Vaccines against Plasmodium vivax and P. falciparum malaria
This involves identifying and prioritising candidate antigens for vaccine development, determining the optimal formulation and delivery of vaccine antigens, and developing assays to measure vaccine-induced immune responses that can be used in vaccine development and clinical trials.
Studies focus on several leading candidate antigens (AMA1, EBAs, PfRh, MSP2), and also aims to identify and characterise other antigens that could be developed as vaccines.
Work is also undertaken on vaccine approaches to induce potent protective immune responses.
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present. We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
Oops!
It looks like something may have gone wrong, and some of the resources required to load the page may not have loaded correctly.
